Samanta
Hernández-García‡
,
Beatriz
García-Cano‡
,
Pedro
Martínez-Rodríguez
,
Paula
Henarejos-Escudero
and
Fernando
Gandía-Herrero
*
Departamento de Bioquímica y Biología Molecular A, Unidad Docente de Biología, Facultad de Veterinaria. Regional Campus of International Excellence “Campus Mare Nostrum”. Universidad de Murcia, Murcia, Spain. E-mail: fgandia@um.es; Fax: +34 868 884147; Tel: +34 868 889592
First published on 16th May 2024
Parkinson's disease is the neurodegenerative motor disorder with the highest incidence worldwide. Among other factors, Parkinson's disease is caused by the accumulation of α-synuclein aggregates in a patient's brain. In this work, five molecules present in the diet are proposed as possible nutraceuticals to prevent and/or reduce the formation of α-synuclein oligomers that lead to Parkinson's disease. The olive oil polyphenols tyrosol, hydroxytyrosol (HT), hydroxytyrosol acetate (HTA) and dihydroxyphenyl acetic acid (DOPAC) besides vitamin C were tested using a cellular model of α-synuclein aggregation and a Caenorhabditis elegans Parkinson's disease animal model. Levodopa was included in the assays as the main drug prescribed to treat the disease as well as dopamine, its direct metabolite. HTA and DOPAC completely hindered α-synuclein aggregation in vitro, while dopamine reduced the aggregation by 28.7%. The Parallel Artificial Membrane Permeability Assay (PAMPA) showed that HTA had the highest permeability through brain lipids among the compounds tested. Furthermore, the C. elegans Parkinson's disease model made it possible to assess the chosen compounds in vivo. The more effective substances in vivo were DOPAC and HTA which reduced the αS aggregation inside the animals by 79.2% and 76.2%, respectively. Moreover, dopamine also reduced the aggregates by 67.4% in the in vivo experiment. Thus, the results reveal the potential of olive oil tyrosols as nutraceuticals against α-synuclein aggregation.
The trigger for PD is the progressive loss of dopaminergic neurons from the substantia nigra and the simultaneous loss of dopaminergic terminals in the caudate-putamen, which is the main projection area of neurons from substantia nigra. However, the etiology of PD is still unknown, with several environmental and genetic factors that may contribute to its physiopathology.4
In terms of the epidemiological approach to PD, it has shown limitations since the earliest studies due to the absence of a biological marker and universally accepted diagnostic criteria. This makes the comparison between the different studies on the disease difficult.5 Recent studies suggest that mitochondrial dysfunction and oxidative stress involving the α-synuclein (αS) protein in the neuronal cells are largely responsible for the accumulation of phosphorylated αS aggregates in the patient's brain.6
Currently, there is no treatment able to cure Parkinson's disease. Available treatments are only focused on the control of symptoms. Levodopa (L-dopa) remains the most prescribed drug for this disease since, unlike dopamine, it is able to cross the blood–brain barrier (BBB) and act on different metabolic pathways at the neuronal level7. Once crossing the blood–brain barrier, L-dopa is metabolized to dopamine by the enzyme DOPA decarboxylase, and the increase of free dopamine leads to the recovery of synaptic transmission of dopaminergic neurons. The patient experiences a remarkable improvement in the classic symptomatology of the disease. However, after a few years, approximately 40% of patients develop secondary complications, characterized by a decrease in the drug's effectiveness, along with the emergence of spontaneous movements.8 Therefore, it is necessary to find alternative treatments for Parkinson's disease to further control the disease evolution. In this scenario, it is of special interest to identify molecules with the potential to interfere with αS aggregation, such as polyphenols. Tyrosols are a class of polyphenols present in different quantities in olive leaves, olive fruits, and extra virgin olive oil.9 Several studies have shown tyrosols’ potent antioxidant properties, and promising results have been obtained in previous experiments on the treatment of neurodegenerative diseases.10,11 Tyrosol is a simple phenolic compound found in a variety of plants, in addition to olives. It has been shown to possess antioxidant and anti-inflammatory properties, which may contribute to the prevention of chronic diseases such as cardiovascular disease and cancer.12 Hydroxytyrosol (HT) is a more potent antioxidant and it is considered one of the most abundant polyphenols in olive oil. It has been shown to have a wide range of health benefits, including the prevention of cardiovascular disease, neurodegenerative diseases, and cancer.12 Its derivative hydroxytyrosol acetate (HTA) is formed during the production of olive oil. It has been shown to have similar antioxidant and anti-inflammatory properties to hydroxytyrosol, but with higher stability and bioavailability.13 This makes HTA a promising candidate to be used as a nutraceutical. Another polyphenol in olive oil found to possess antioxidant and anti-inflammatory properties is dihydroxyphenyl acetic acid (DOPAC). It is also a metabolite of dopamine, a neurotransmitter involved in various brain functions.14
On the other hand, vitamin C (sodium ascorbate) is a water-soluble antioxidant, present in citrus fruits such as oranges and grapefruits. Several studies concluded that the intake of vitamin C does not substantially affect the risk of PD in human patients;15 however, Nagayama and coauthors reported that vitamin C improved the absorption of levodopa in elderly Parkinson's patients and concluded that a combined therapy of levodopa and ascorbic acid may ameliorate the disease symptoms.16
In this study, the C. elegans mutant strain NL5901 was used as a model of Parkinson's disease. Although C. elegans lacks the orthologue genes for α-synuclein (PARK1) and leucine-rich repeat kinase 2 (LRRK2), the facile manipulation of its genome allows the transgenic expression of human genes and the study of neuronal degeneration.17 The available mutant strains WLZ1 and WLZ3 that overexpress human LRRK2 are used as a nematode model for Parkinson's disease.18 Meanwhile, C. elegans strains that express human αS under the control of specific promoters allow the visualization, localization, and quantification of αS aggregates in vivo.19 For example, strain NL5901 expresses αS fused with YFP in an animal's muscles, while strain ERS100 overexpresses α-synuclein fused with Venus in dopaminergic neurons marked with mCherry. Furthermore, Parkinson's neurodegeneration can be simulated by exposing nematodes to neurotoxins. Exposure to rotenone, a plant neurotoxin, or 6-OHDA (6-hydroxydopamine), a precursor of 1-methyl-4-phenylpyridinium (MPP), induces programmed cell death in dopaminergic neurons in the nematode.20 Thus, the simple genetic manipulation and different mutant strains of C. elegans available offer multiple possibilities for the discovery of new targets and treatments for Parkinson's disease.
The lack of treatments aimed to reduce αS aggregation encouraged this study to assess the potential of various molecules present in the diet as possible nutraceuticals to prevent or reduce the formation of αS oligomers that cause Parkinson's disease. Olive oil polyphenols (tyrosols), dopamine, levodopa and vitamin C (Fig. 1) were evaluated as αS anti-aggregation agents using a cellular model of αS aggregation based on bimolecular fluorescence complementation (BiFC) technology and C. elegans mutant strain NL5901 as an animal model of Parkinson's disease.
The hypothesis of this study is that naturally occurring polyphenols, such as olive oil tyrosols, could reduce αS aggregation due to their structure, chemical characteristics, and antioxidant properties.
The BiFC cellular model was used following the authors' published protocol. Briefly, cells were cultured in LB broth until an optical density (OD600) of 0.2–0.3 was reached and then diluted to 0.03 with fresh LB supplemented with ampicillin (100 μg mL−1), chloramphenicol (25 μg mL−1), and 1 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) as an inducer. The assays were performed in black 96-well plates and monitored using a Synergy HT microplate reader from BIO-TEK (Winooski, VT, USA). One hundred microliters of the diluted cell mixture were placed in each well, followed by the selected compound, and completed with fresh LB up to 300 μL. For each concentration, 5 replicates were made, and cell-free controls and compound-free controls were also performed. Measurements were set every 15 minutes in fluorescence mode (λex 485 nm and λem 530 nm) with the temperature fixed at 37 °C.
The fluorescence intensity of the cells was determined with ImageJ (NIH) software.22 Briefly, each fluorescence image was divided into red, blue, and green channels, from which green was selected. Then, the threshold tool was applied so that the program could define the fluorescent zones and measure the intensity.
The donor plates were filled with 300 μL of each compound. Then, the filter membrane of the acceptor microplate was coated with 4 μL of the PBL solution, prepared at 20 mg mL−1 in dodecane, and 200 μL of PBS were placed in the acceptor wells. Thereafter, the acceptor plate was gently placed into the donor plate and incubated at 37 °C for 4 hours in a humidity chamber. At the end of the assay, the molecules were detected in the acceptor and donor plates by HPLC using a C18 column. Compound permeability was calculated with the following equation (eqn (1))
![]() | (1) |
![]() | (2) |
Verapamil is a control classified as a high-permeability drug and theophylline is a low-permeability drug.
Screening experiments were performed with natural molecules of high biological interest to find compounds able to delay and/or decrease the αS aggregation in the BiFC model. The compounds chosen were tyrosol, hydroxytyrosol, hydroxytyrosol acetate, DOPAC and dopamine. These molecules at low concentrations were mildly effective (Fig. S1 and Table S1†) due to the molecules’ oxidation, as evidenced by a dark coloration in the test flasks at the end of the experiments (Fig. S1F†), and by the exponential increase in fluorescence not related to αS aggregation. Therefore, the concentration of the molecules was increased and L-dopa and vitamin C (sodium ascorbate) were added to the screening assays. Sodium ascorbate at 1 mM was used to supplement each test compound as an antioxidant in order to avoid the autoxidation of the molecules and the formation of o-quinones.27 Once the complementary treatment with sodium ascorbate was established, measurements of the interference of the αS aggregation were performed using tyrosol, hydroxytyrosol, hydroxytyrosol acetate, DOPAC, and dopamine in a range of concentrations from 0.0001 to 15 mM (Fig. 2B–F). The concentration range for L-dopa was lower (Fig. 2G) due to its low solubility in water (1.14 to 0.38 mM). Additionally, sodium ascorbate was also tested in a concentration range from 0.01 to 15 mM (Fig. 2H). Overall, the tested compound reduced the oligomerization rate of αS in comparison with the controls in the cell model, suggesting the effectiveness of these molecules as αS anti-aggregation agents. Although most compounds at concentrations below 1 mM did not reduce the aggregation rate, hydroxytyrosol acetate (Fig. 2C) and sodium ascorbate (Fig. 2H) significantly reduced the rate of oligomer aggregation by 16.9% and 7.7%, respectively, at a concentration of 0.1 mM. Furthermore, L-dopa was able to reduce the rate of αS oligomerization by 12.0% at 0.38 mM (Fig. 2G).
The reduction percentages given in ESI Table S1† were calculated with respect to the control without ascorbate, while in ESI Table S2,† they are referred to the control with 1 mM sodium ascorbate. Therefore, in some cases, the percentage of reduction shown in ESI Table S1 is higher than that in ESI Table S2.† In comparison with the ascorbate-free control, hydroxytyrosol acetate reduced the aggregation rate by 55.0%. It is noteworthy that the effects of sodium ascorbate combined with hydroxytyrosol acetate were not additive but synergistic, i.e., the effect on the αS aggregation rate using the combination of both substances is higher than that with the addition of the individual substances.
The treatment with 10 and 15 mM DOPAC totally hindered the αS aggregation (Fig. 2E, ESI Table S2†), while hydroxytyrosol acetate and sodium ascorbate at 15 mM decreased the rate of aggregate formation by 99.6 and 80.2%, respectively (Fig. 2C and H). Furthermore, tyrosol and hydroxytyrosol reduced the aggregation rate by 67.0 and 47.0%, respectively (Fig. 2B and C). Dopamine had a lower effect (Fig. 2F) compared to the other compounds tested (28.7%), and the effect was not dose-dependent. The results showed that the effective concentrations in vitro are high, and thus it could be difficult to achieve these concentrations by only consuming hydroxytyrosol-containing foods. Extra virgin olive oil (EVOO) has an average hydroxytyrosol concentration of 14.32 mg kg−1, while olives like Spanish green olives and Greek kalamata olives have a concentration of 170–510 mg kg−1 and 250–760 mg kg−1, respectively.28 As a result, following a Mediterranean diet, the consumption of this molecule could be up to 5 mg per day, although in some clinical trials, the dose has been increased to 15–25 mg per day. Furthermore, the EFSA considered 50 mg kg−1 as a safe daily intake of hydroxytyrosol in adults,29 so efforts have been made to increase the consumption of this beneficial ingredient. Supplements rich in this compound are already available for the consumer. Furthermore, it has been added to processed foods as a preserving agent and the EFSA authorized hydroxytyrosol addition to fish and vegetable oils (215 mg kg−1) and spreadable fats (175 mg kg−1).29 The incorporation of hydroxytyrosol into food products increases their health-promoting benefits and lengthens their shelf life because of the antibacterial and antioxidant properties of the molecule. Moreover, several studies with mice showed that hydroxytyrosol was non-toxic up to 500 mg per kg per day (ref. 30) and Pérez de la Lastra and coauthors31 proposed a dose of 800 mg per day for adult humans to treat SARS-CoV-2. Thus, it could be healthy to increase hydroxytyrosol consumption in the diet.
The parameter EC50 is a value widely used in pharmacology to estimate the efficacy of a drug. It can be defined as the required concentration of a molecule to obtain 50% of the desired effect. The more effective a compound is, the lower the IC50 will be. The results on the aggregation rate were adjusted to the Hill equation (eqn (1)) to obtain the EC50 of the molecules.
![]() | (3) |
The compounds with lower EC50 values were hydroxytyrosol acetate (1.97 mM) and sodium ascorbate (2.8 mM), while DOPAC, hydroxytyrosol, and tyrosol had values of 7.5, 7.6, and 22.9 mM, respectively (ESI Fig. S2 and Table S3†). Numerous studies have described small molecules capable of inhibiting αS aggregation using different experimental methods. In 2006, Masuda and co-authors investigated the effects of 79 compounds on αS oligomerization in vitro, obtaining IC50 values in the micromolar range for some compounds such as baicalein (flavone, 8.2 μM), delfinidine (anthocyanidine, 6.5 μM), or vitamin E (α-tocopherol, 10.9 μM).32 Further studies have shown that tolcapone and entacapone are potential inhibitors of αS, used at micromolar concentrations. These molecules belong to the class of multifunctional drugs used as adjuvants for L-dopa, as they can inhibit COMT (catechol-O-methyltransferase), act as antioxidants, and inhibit protein aggregation.33
The results obtained by the BiFC technique used to assess αS aggregation in the presence of bioactive molecules were visually verified by fluorescence microscopy (Fig. 3B–H). Cells without IPTG as an inducer did not show any fluorescence (Fig. 3B); in contrast, the control cells induced with IPTG showed the highest fluorescence (Fig. 3C). Both results are consistent with the aggregation curves obtained and the BiFC technical foundations. Compared to the control cells, all compounds decreased the fluorescence and therefore the αS oligomerization. The most relevant compounds were hydroxytyrosol acetate and DOPAC, assayed at a concentration of 15 mM and stabilized with sodium ascorbate at 1 mM. This caused the complete disappearance of fluorescence (Fig. 3G and H). At the same concentration, sodium ascorbate managed to decrease the fluorescence by 78.8% (Fig. 3E). In addition, a low dose (1 mM) of vitamin C and hydroxytyrosol reduced the fluorescence intensity of the cells by 46.3% and 50.0%, respectively.
![]() | ||
Fig. 3 Microscopy of the BiFC αS aggregation model. (A) Bimolecular fluorescence complementation technology scheme used to measure αS aggregation in vitro. Vn is the Venus N-terminal and Vc is the Venus C-terminal. (B–H) Representative fluorescence images of the E. coli cells; raw images are shown in Fig. S4.† (B) Negative control (without an inducer). (C) Positive control (cells induced with IPTG). The arrowheads point to the fluorescent cells. (D) Treatment with sodium ascorbate (1 mM). (E) Treatment with sodium ascorbate (15 mM). (F) DOPAC, 1 mM, stabilized with 1 mM sodium ascorbate. (G) DOPAC, 15 mM, stabilized with 1 mM sodium ascorbate. (H) Treatment with HTA (15 mM) stabilized with sodium ascorbate (1 mM). Scale bar: 20 μm. (I) Measurements of cell fluorescence intensity. (a) Control cells induced with IPTG. (b) Treatment with sodium ascorbate at 1 mM. (c) Treatment with sodium ascorbate at 15 mM. (d) Treatment with 1 mM DOPAC and 1 mM sodium ascorbate. (e) Treatment with DOPAC (15 mM) and sodium ascorbate (1 mM). (f) Treatment with HTA (15 mM) and sodium ascorbate (1 mM). Data are presented as mean ± standard deviation. *p-Value ≤ 0.05 by ANOVA test using Bonferroni post hoc test. |
It is expected that αS-YFP fusion inclusions, which appear to be unevenly distributed fluorescent dots in C. elegans (Fig. 5), could represent the primary cytotoxic αS species present in the post-mortem brain tissue of human patients affected by the disease.35
In the nematodes, the αS protein expression and aggregation develop with aging, and show a maximum at the 4th day of adulthood (Fig. 5C1, and Fig. 6).
After 48 hours of treatment, all the bioactive molecules, except L-dopa, were able to hinder the aggregation of αS in the nematodes. Dopamine and DOPAC were the molecules that most decreased the αS aggregates in vivo on the first day of adulthood – by 70.8% and 74.8%, respectively (Fig. 5 and 6). However, the most stable were hydroxytyrosol acetate and DOPAC, since the antiaggregating effect was maintained over time. By the seventh day of adulthood, these molecules reduced the αS aggregates in vivo by 71.8% and 71.0%, respectively. Furthermore, the number of aggregates formed was also measured (Fig. S5B†), and the results obtained were similar to those obtained by the quantification of the fluorescence. DOPAC and hydroxytyrosol acetate reduced the number of aggregates by 68.6% and 58.1%, respectively, on the 4th day of adulthood. Interestingly, L-dopa did not significantly reduce the formation of aggregates on C. elegans, while dopamine, the decarboxylated metabolite of L-dopa, and the active principle within the blood–brain barrier, was effective in hindering the αS aggregation. Dopamine may be more effective than L-dopa on C. elegans, probably because the nematode lacks a blood–brain barrier, although the glial cells that cover the cephalic sensory neurons may act as a simple blood–brain barrier.36 Other studies have tested the effect of small molecules on αS aggregation. Saewanee and coauthors used the antidiabetic drug metformin on the C. elegans NL5901 strain, and the results showed that metformin at 15 mM reduced the αS aggregation in vivo by 19.6% on the fourth day of adulthood.37 Hughes and coauthors tested levodopa (L-dopa) at 1 mM on the same C. elegans strain, and the results obtained indicated that L-dopa at 1 mM did not have an effect on αS aggregation; however, at 3 mM the aggerates were reduced by 30%. The authors also tested other molecules and concluded that valproic acid, bexarotene, galantamine, and tetrabenazine reduced the synuclein plaques when used in a concentration range of 1 to 3 mM.38
The inhibitory effects of hydroxytyrosol acetate and DOPAC on αS aggregation can be attributed to various underlying mechanisms. Hydroxytyrosol acetate is a metabolite of dopamine that has been shown to possess antioxidant properties.12 It can scavenge reactive oxygen species and prevent oxidative stress, which is known to promote the aggregation of αS. Additionally, hydroxytyrosol acetate can modulate the activity of enzymes involved in αS aggregation, such as tyrosinase and monoamine oxidase, thereby reducing the formation of toxic aggregates. Meanwhile, DOPAC is a major metabolite of dopamine produced by the action of the enzyme monoamine oxidase.39 DOPAC has been found to inhibit αS aggregation by direct interaction with αS and so, it disrupts the fibrillation process, thus preventing the formation of toxic aggregates.40 Furthermore, hydroxytyrosol acetate can modulate the expression of proteins able to hinder αS aggregation. Also, hydroxytyrosol acetate has been shown to increase the expression of heat shock proteins, which are known to have chaperone activity and can assist in the appropriate folding of proteins. This can prevent the misfolding and aggregation of αS.41 Overall, the inhibitory effects of hydroxytyrosol acetate and DOPAC on αS aggregation may involve, in addition to the direct interaction with the protein demonstrated in the bimolecular fluorescence cellular model, a combination of antioxidant properties, modulation of related enzyme activities, and regulation of the cellular mechanisms of protein folding and degradation.
The Parkinson's disease model of Caenorhabditis elegans used allowed the evaluation of the effects of the selected molecules in vivo. The compounds that decreased αS aggregation the most in vivo were HTA (76.2%) and DOPAC (79.2%). Moreover, dopamine also reduced the aggregates by 67.4% in the in vivo assay. Additionally, the compounds HTA and DOPAC also exhibited a positive effect on the longevity of C. elegans, increasing the average lifespan by 28.5% and 25.6%, respectively.
As hypothesized, naturally occurring tyrosols were able to reduce αS aggregation in vitro and in vivo. Furthermore, due to their structure, the compounds performed better than L-dopa and dopamine in the PAMPA permeability assay. Thus, the results of this work open a new avenue to the use of olive oil dietary molecules as nutraceuticals to treat Parkinson's disease, with HTA and DOPAC being the polyphenols with the most promising results.
Footnotes |
† Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d4fo01663g |
‡ Co-first authors. |
This journal is © The Royal Society of Chemistry 2024 |